MedTrace Logo

DYNAmic Immune Microenvironment of HCC Treated With atezolIzumab Plus bevaCizumab

NCT04954339 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2025-05-31

No results posted yet for this study

Summary

Part I (Clinical trial setting): A single-arm phase II study to investigate the efficacy of neoadjuvant atezolizumab (T) + bevacizumab (A) in patients with potentially resectable BCLC stage B/C or high risk resectable hepatocellular carcinoma (HCC) (n = 45)

Part II (Biomarker study setting): Exploratory translational research will be conducted using samples obtained from Part 1 (n =45) and those acquired from an independent cohort of treatment-naïve HCC patients (n = 15).

Conditions

Interventions

DRUG

Aatezolizumab plus Bevacizumab

Two cycles of naeoadjuvant atezolizumab (1200 mg) plus bevacizumab (15 mg/kg) prior to surgical resection and four cycles of adjuvant atezolizumab (1200 mg) plus bevacizumab (15 mg/kg) after the surgery will be administered.

Sponsors & Collaborators

  • Tae Won Kim

    lead OTHER

Principal Investigators

  • Tae Won Kim · Asan Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-29
Primary Completion
2026-06-30
Completion
2026-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04954339 on ClinicalTrials.gov